ABSTRACT
Background
Sentinel lymph node (SLN) biopsy has become a standard of care for axillary lymph node staging in breast cancer and appears suitable for virtually all patients with clinically node-negative (cN0) invasive disease. However, its role in Paget’s disease of the breast, a condition in which invasion may or may not be present, remains undefined.
Methods
Among 7,083 consecutive SLN biopsy procedures, we retrospectively identified 39 patients with Paget’s disease of the breast. Nineteen patients had no associated clinical/radiographic features (“Paget’s only”), and 20 patients had associated clinical/radiographic findings (“Paget’s with findings”).
Results
The mean ages for the Paget’s alone and with findings groups were 63.6 and 49.6 years, respectively. The use of breast conservation therapy was 32% in the Paget’s alone group and 10% in the Paget’s with findings group. Invasive carcinoma was found in 27% of patients in the Paget’s alone group and 55% of patients in the Paget’s with findings group. The success rate of SLN biopsy was 98%, and the mean number of SLNs removed was 3 in both groups. In the entire cohort of Paget’s disease, 28% (11/39) of the patients had positive SLNs (11%, Paget’s alone; 45%, Paget’s with findings).
Conclusion
In our “Paget’s only” cohort, invasive cancer was found in 27% of cases and positive SLNs in 11%. SLN biopsy should be considered in all patients with Paget’s disease of the breast, whether associated clinical/radiographic findings are present.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ashikari R, Park K, Huvos AG, Urban JA. Paget’s disease of the breast. Cancer 1970; 26(3):680–5
Nance FC, DeLoach DH, Welsh RA, Becker WF. Paget’s disease of the breast. Ann Surg 1970; 171(6):864–74
Vijayakumar V, Boerner PS, Jani AB, Vijayakumar S. A critical review of variables affecting the accuracy and false-negative rate of sentinel node biopsy procedures in early breast cancer. Nucl Med Commun 2005; 26(5):395–405
Klauber-DeMore N, Tan LK, Liberman L, Kaptain S, Fey J, Borgen P, Heerdt A, Montgomery L, Paglia M, Petrek JA, Cody HS, Van Zee KJ. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000; 7(9):636–42
Linehan DC, Hill AD, Akhurst T, Yeung H, Yeh SD, Tran KN, Borgen PI, Cody HS. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol 1999; 6(5):450–4
Polgar C, Orosz Z, Kovacs T, Fodor J. Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 2002; 94(6):1904–5
Marshall JK, Griffith KA, Haffty BG, Solin LJ, Vicini FA, McCormick B, Wazer DE, Recht A, Pierce L J. Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results. Cancer 2003; 97(9):2142–9
International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990; 335(8705):1565–8
Author information
Authors and Affiliations
Corresponding author
Additional information
Previous presentations: Sukumvanich P, Bentrem DJ, Cody HS, Brogi E, Fey JV, Borgen P, Gemignani ML. The Role of Sentinel Lymph Node Biopsy in Paget Disease of the Breast. Society of Clinical Oncology, Orlando, FL. May 16, 2005. (Accepted for poster presentation).
Rights and permissions
About this article
Cite this article
Sukumvanich, P., Bentrem, D.J., III, H.S.C. et al. The Role of Sentinel Lymph Node Biopsy in Paget’s Disease of the Breast. Ann Surg Oncol 14, 1020–1023 (2007). https://doi.org/10.1245/s10434-006-9056-2
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-006-9056-2